XRAY Stock Recent News
XRAY LATEST HEADLINES
CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced its financial results for the fourth quarter and full year of 2024.
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
Evaluate the expected performance of Dentsply (XRAY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
XRAY is likely to have faced a tough fourth quarter with Byte's revenue loss, weak U.S. equipment demand and implant pressures.
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
NEW YORK, NY / ACCESS Newswire / February 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on behalf of long-term stockholders following a class action complaint that was filed against Dentsply on November 26, 2024 with a Class Period from May 6, 2021 to November 6, 2024. Our investigation concerns whether the board of directors of Dentsply have breached their fiduciary duties to the company.
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.
CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business (“Wellspect”).